Digital PCR (d-PCR) Market Key Players, Growth Analysis during 202O-2025

Digital polymerase chain reaction (d-PCR) is considered a next-generation PCR technology offering rapid, sensitive quantification of nucleic acid when compared to the conventional PCR technology. Digital PCR is highly precise, where each sample partitioned into a number of individualized reactions or as droplets in a droplet-based digital PCR. These partitioned droplets are analyzed after a separate PCR reaction takes place per single sample, and the absolute number of molecules present in the sample is calculated.

BIS Research healthcare experts have found digital PCR (d-PCR) market to be one of the most rapidly evolving markets and the global market for digital PCR (d-PCR) is predicted to grow at a CAGR of 17.57% over the forecast period of 2020-2025. The market is driven by certain factors, which include the rising incidence of infectious disease, such as recent pandemic COVID-19, inciting the development of high-throughput diagnostics, increasing adoption of personalized medicine for the screening and diagnostics of genetic disorders, and significant external funding for executing R&D exercises.

The market is favored by the development of digital PCR-based solutions for early diagnosis and rare mutation detection with absolute quantification of target sample. The gradual increase in the prevalence of infectious disease due to pandemic COVID-19 globally has furthered the digital PCR (d-PCR) market.
Furthermore, several diagnostic companies are focusing on the development of digital PCR diagnostics with higher sensitivity and low turn-around time to benefit the patients, enabling patient-based outcomes.

Market Segmentation

• Product Type – Assays and Reagents, Platforms, Accessories, and Instruments

• Application- Clinical, Environmental Monitoring, Food and Agriculture and Others

• End User – Hospital and Clinics, Academic and Research Institutions, Diagnostic Centers, and Other End Users

Regional Segmentation

• North America – U.S., Canada

• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)

• Latin America – Brazil, Mexico, and Rest-of-the-Latin America

• Rest-of-the-World

Growth Drivers

• Rising Incidence of Infectious Disease, such as recent pandemic COVID-19, Inciting the Development of High-throughput Diagnostics

• Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders

• Significant External Funding for Executive R&D Exercises

Market Challenges

• Shortage of Skilled Professionals and Trained Lab-Technicians

• High Cost of Platforms Associated with Digital-PCR

Market Opportunities

• Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations

• Technological Advancements in the development of Digital PCR-based Solutions

• Increased Use of Digital PCR-Based Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan

Key Companies Profiled

Thermo Fisher Scientific, Bio-Rad Laboratories, Inc.., Optolane Technologies, Inc., Qiagen NV, Sysmex Corporation, SAGA Diagnostics AB, Stem Genomics, Fluidigm Corporation, Combinati, Merck KGaA, JN Medsys, Stilla Technologies, Dropworks, Inc. Naveris, Inc. Genetron Holdings Limited.

Request a Sample - https://bisresearch.com/requestsample?id=958&type=download

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Market Research Reports

Search This Blog